Memory Disorders Market By Disorder Type (Alzheimer’s Disease, Mild Cognitive Impairment, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia); By Diagnostic Method (Neuroimaging, Biomarker Testing, Cognitive Assessment Tools, Genetic Testing); By Treatment Type (Cholinesterase Inhibitors, NMDA Antagonists, Disease-Modifying Therapies, Cognitive/Behavioral Interventions); By End User (Hospitals & Memory Clinics, Primary Care Providers, Long-Term Care Facilities, Home-Based Care); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Memory Disorders Market is projected to grow at a CAGR of 6.7% , reaching an estimated value of USD 10.9 billion in 2024 and poised to cross USD 16.2 billion by 2030 , according to Strategic Market Research

 

Memory disorders — from mild cognitive impairment to Alzheimer’s and frontotemporal dementia — are no longer fringe diagnoses. As life expectancy rises and diagnostic methods evolve, these conditions are commanding sharper attention from clinicians, caregivers, pharma companies, and policymakers alike. Between 2024 and 2030, this market is not only expanding in volume but also redefining its identity through biomarker-led diagnostics, AI-supported cognitive tools, and disease-modifying treatment candidates.

 

Globally, the most noticeable tailwind comes from aging demographics. Countries like Japan, Italy, Germany, and South Korea now report that more than 20% of their populations are aged 65 or older — a demographic slice with the highest risk of memory loss-related diseases. But age isn’t the only variable. Research is uncovering earlier-onset forms of cognitive decline, including post-traumatic memory loss, chemobrain in oncology patients, and even long COVID-related cognitive fog — all of which are widening the addressable market.

 

At the same time, diagnosis and disease staging are shifting from clinical interviews to precision diagnostics. Advances in PET imaging , CSF biomarkers , and blood-based assays are compressing the diagnostic timeline, giving way to earlier interventions. This isn’t just about convenience — it’s about giving therapies a better shot at modifying disease progression.

 

Strategically, the memory disorders market sits at the intersection of neuroscience, digital health, and therapeutics . Stakeholders span several domains:

• Biopharma firms racing to develop anti-amyloid or tau-targeting drugs

• Neuroimaging OEMs enabling early detection through amyloid PET scans and volumetric MRIs

• Tech startups offering gamified cognitive training tools and passive monitoring apps

• Payers and health systems investing in early detection to delay long-term care costs

• Public health bodies that see dementia as both a clinical and economic threat

To be honest, memory loss used to be considered inevitable — just part of getting old. That’s changing fast. The conversation now centers around early detection, lifestyle-linked prevention, and tech-enabled slowing of cognitive decline.

 

Market Segmentation And Forecast Scope

The memory disorders market is evolving from a narrow clinical niche into a multidimensional opportunity space. Diagnostic technologies, therapeutic pipelines, and care delivery models are diversifying fast — and so is how the market segments.

By Disorder Type

• Alzheimer’s Disease Still the dominant segment, accounting for over 52% of the global market in 2024 Alzheimer's remains the most studied and most publicly recognized memory disorder, attracting the lion’s share of R&D funding and commercial trials.

• Mild Cognitive Impairment (MCI) A growing early-stage market. MCI is gaining diagnostic visibility as more individuals undergo proactive cognitive screening — especially in urban, aging populations.

• Vascular Dementia Common in stroke-prone populations and emerging economies. It’s underdiagnosed but significant, particularly in Asia and Eastern Europe.

• Frontotemporal Dementia (FTD), Lewy Body Dementia, and Others Smaller in market size but gaining traction as awareness and differential diagnostic tools improve.

Insight: MCI is emerging as a key battleground for digital and pharmaceutical players — because catching memory decline earlier gives therapies a longer runway to work.

 

By Diagnostic Method

• Neuroimaging (MRI, PET) Often used to rule out other neurological conditions and track structural or metabolic brain changes. PET scans , especially amyloid and tau tracers, are becoming more widely reimbursed in high-income countries.

• Biomarker Testing (CSF and Blood-Based) The fastest-growing diagnostic category. With recent approvals of plasma-based Alzheimer’s markers, access is expanding beyond academic centers.

• Cognitive Assessment Tools Includes digital cognitive batteries, clinician-led memory exams, and mobile-based tools. Many of these are being deployed in primary care or telehealth settings.

• Genetic Testing Still niche, but rising in families with early-onset Alzheimer’s or strong hereditary patterns.

 

By Treatment Type

• Cholinesterase Inhibitors and NMDA Antagonists Longstanding standard-of-care drugs like donepezil or memantine dominate current prescriptions — primarily for symptom management.

• Disease-Modifying Therapies (DMTs) Gaining ground fast. The launch of amyloid-targeting biologics and tau-inhibiting candidates is redefining the pipeline, though pricing, efficacy, and safety remain debated.

• Cognitive Enhancement and Behavioral Therapies Covers everything from non-pharmacologic interventions to digital therapeutics and neuromodulation techniques.

 

By End User

• Hospitals and Specialty Neurology Clinics Primary settings for diagnosis, biomarker testing, and treatment initiation — especially for complex or high-risk cases.

• Home Care and Memory Support Facilities A rising segment as aging-in-place trends accelerate and tech-enabled remote monitoring becomes more common.

• Academic Research Centers Act as hubs for biomarker studies, clinical trials, and innovation in early-stage detection protocols.

 

By Region

• North America Currently holds the largest share of the global market, with strong investment in PET imaging and high uptake of newly approved therapies.

• Europe Rapidly adopting blood-based biomarkers and centralized dementia registries. The EU’s cross-border healthcare framework is also enabling broader clinical trial access.

• Asia Pacific Fastest-growing region. Driven by aging demographics, improving access to diagnostics, and a surge in neurological research funding from countries like Japan, China, and South Korea.

• Latin America, Middle East, and Africa (LAMEA) Still early in market development. Most memory disorders go undiagnosed, but mobile-based screening tools and public-private pilot programs are starting to close the gap.

Scope Note: Segmentation here reflects more than just clinical subtypes. It shows how new care models — from blood tests at home to AI-led memory apps — are turning memory care into a broader ecosystem play.

 

Market Trends And Innovation Landscape

The memory disorders market isn’t just expanding — it’s morphing. We’re seeing a steady shift from symptom management to early detection and disease modification, fueled by advances in neurobiology, diagnostics, and digital health. This next wave of innovation is coming from all sides: pharma, imaging, AI, and even consumer tech.

Blood-Based Biomarkers Are Changing the Game

For decades, confirming Alzheimer’s or other memory disorders meant invasive spinal taps or costly PET scans. That’s changing. Recent breakthroughs in plasma-based biomarkers — especially for amyloid-beta and phosphorylated tau — are rewriting the playbook for screening and staging. A simple blood test could now serve as the first filter in clinical workflows, especially in primary care or resource-limited settings.

This is more than convenience. Earlier, faster, and cheaper screening allows health systems to triage patients better, direct them into trials faster, and monitor progression longitudinally. And with multiple biotech startups now pushing FDA submissions, this space is heating up fast.

One neurology researcher put it simply: “Blood tests will do for dementia what HbA1c did for diabetes — normalize proactive testing.”

 

AI-Powered Cognitive Tools Are Gaining Ground

Cognitive decline is hard to track — especially outside the clinic. That’s where AI-based apps and digital cognitive assessment platforms are stepping in. These tools now run memory games, monitor speech patterns, or analyze typing behavior — all to flag early signs of decline before formal symptoms show.

Beyond detection, AI is also powering imaging. New deep learning models trained on thousands of brain scans are helping radiologists detect hippocampal atrophy, cortical thinning, or vascular lesions with much higher accuracy — sometimes even before symptom onset.

Startups are also building passive cognitive monitoring tools embedded in smartwatches, phone usage, or daily activity patterns. The idea: don’t wait for a memory complaint. Detect change subtly, in the background.

 

Disease-Modifying Drugs Are Finally Getting Real — But It’s Complicated

After years of trial failures, the FDA's controversial approval of the first anti-amyloid monoclonal antibody (followed by others) opened the door for disease-modifying therapies. More importantly, it sent a signal to pharma companies: progress is possible.

That said, rollout challenges remain. These therapies are expensive, require infusion infrastructure, and come with safety concerns like ARIA (amyloid-related imaging abnormalities) — which means monitoring is just as critical as prescribing.

The second wave of innovation is now focusing on anti-tau , neuroinflammation blockers , and synaptic modulators — all aiming to target memory loss from different biological angles.

 

Digital Therapeutics Are Coming Into Their Own

Digital therapeutics (DTx) — once dismissed as cognitive games — are now being designed with clinical intent. Several platforms are now undergoing FDA review as adjunctive tools for mild cognitive impairment , aiming to slow progression through structured memory exercises and behavioral interventions.

It’s not science fiction anymore. There are now VR-based training platforms for memory recall, AI-coaches that guide lifestyle changes, and digital diaries that help track and analyze patterns of confusion.

 

Multimodal Imaging is Going Mainstream

The integration of structural MRI, functional MRI (fMRI), PET, and diffusion tensor imaging (DTI) is pushing the boundaries of what’s detectable in early-stage disease. Academic centers are using multimodal imaging overlays to stage disease far earlier and plan more targeted interventions — particularly in MCI or preclinical Alzheimer’s.

More importantly, imaging is now being coupled with AI, wearable EEG, and longitudinal cognitive data — creating a 360-degree view of a patient’s memory trajectory.

 

Partnerships Are Accelerating Innovation

There’s a notable uptick in cross-sector collaboration:

• Pharma companies partnering with AI startups to streamline trial recruitment

• Neurotech firms working with insurers to create reimbursable pathways for digital memory tools

• Government agencies and NGOs piloting early-screening programs using mobile apps in low-resource areas

Bottom line: the innovation curve isn’t linear. It’s converging. Memory care is no longer just a neurologist’s job — it’s a whole new digital, diagnostic, and therapeutic frontier.

 

Competitive Intelligence And Benchmarking

Competition in the memory disorders market used to be about blockbuster drugs. Today, it’s a much more layered game — one that spans therapeutics, diagnostics, digital tools, and even AI-enabled care pathways. While pharmaceutical giants still lead the charge on disease-modifying therapies, newer entrants are disrupting adjacent spaces like early screening, cognitive monitoring, and biomarker development.

Here’s how the current competitive landscape is taking shape:

Biogen

Biogen has long been a dominant force in neurodegeneration. Its early focus on Alzheimer’s therapies — particularly anti-amyloid monoclonal antibodies — positioned it at the forefront of disease-modifying drug development. The FDA approval of one such therapy sparked debate, but also opened commercial pathways. That said, safety concerns and payer skepticism around cost-effectiveness have challenged uptake.

Biogen’s strategy hinges on pushing deeper into diagnostics and companion biomarker programs to better identify eligible patients and support real-world evidence generation.

 

Eli Lilly

Lilly’s Alzheimer’s pipeline is among the most aggressive in the space. The company is investing heavily in anti-amyloid and anti-tau mechanisms , with several late-stage trials in motion. Unlike some rivals, Lilly is leaning into blood-based biomarker integration as part of its strategy — hoping to build out a more holistic ecosystem from detection to treatment.

Eli Lilly’s strength is in combining biologics expertise with growing diagnostic partnerships, aiming to dominate both drug and monitoring revenue streams.

 

Roche / Genentech

Roche is positioning itself through a two-pronged approach: biologics for disease modification and CSF/plasma diagnostics through its diagnostics division. Genentech (a Roche subsidiary) is running trials for both tau-targeting agents and inflammation-focused approaches, which may complement rather than replace amyloid therapies.

The company is also backing early-stage digital cognitive assessment platforms , especially in European pilot markets, where screening infrastructure is more centralized.

 

Eisai

A key partner to Biogen in co-developing one of the first amyloid therapies to receive regulatory approval, Eisai is continuing to invest in long-term follow-up data and real-world observational studies to strengthen the clinical case for these agents. Its Japan base also positions it well in Asia, where dementia prevalence is rising fastest.

 

Cognito Therapeutics

A standout among neurotech players, Cognito is developing non-invasive neuromodulation therapies using light and sound stimulation to target neural oscillations linked to memory and cognition. Though early-stage, it represents a new direction: targeting brainwave patterns instead of proteins.

This kind of innovation is being closely watched by both investors and incumbents — especially if it offers lower-risk alternatives to biologics.

 

Cogstate

An emerging leader in digital cognitive assessment , Cogstate provides tools for both clinical trial cognitive monitoring and in-clinic cognitive screening. It’s widely used by pharma companies and academic institutions looking to shorten recruitment timelines and improve detection of subtle cognitive changes.

Digital-first platforms like Cogstate are increasingly essential for both decentralized trials and early detection programs in public health systems.

 

Competitive Benchmarks at a Glance:

Category	Leaders	Strategy
Therapeutics (Anti-Amyloid / Anti-Tau)	Biogen, Eli Lilly, Roche	Targeting disease biology; facing scrutiny over pricing and real-world efficacy
Diagnostics (Biomarkers, Imaging)	Roche Diagnostics, Fujirebio, C2N Diagnostics	Commercializing CSF and plasma testing; pursuing payer validation
Digital Cognitive Tools	Cogstate, Altoida, Neurotrack	Offering scalable, low-cost early detection tools
Neurotech / Alternative Therapies	Cognito Therapeutics, Neurable	Exploring novel brain stimulation and monitoring modalities

To be honest, this isn’t a winner-takes-all market. Success will come from ecosystem thinking — companies that link diagnosis, treatment, and long-term monitoring into a seamless care journey will win more trust and traction.

 

Regional Landscape And Adoption Outlook

The global memory disorders market doesn’t grow at the same pace everywhere. Diagnostic access, aging demographics, reimbursement policies, and cultural perceptions of cognitive decline vary sharply from one region to the next. Some countries are investing heavily in early detection and public health programs, while others are just beginning to acknowledge the rising burden of dementia.

North America

Still the most advanced and commercially active region for memory disorders, North America accounts for the largest market share in 2024 . The U.S. leads with its combination of clinical trial infrastructure, insurance reimbursement for neuroimaging and biomarker testing , and growing consumer awareness around cognitive health.

Recent FDA approvals of disease-modifying drugs have accelerated the use of PET imaging , CSF testing , and even plasma biomarker diagnostics in high-risk populations. Academic centers like Mayo Clinic and UCSF are spearheading integrated memory clinics combining neurology, psychiatry, and digital cognitive monitoring.

That said, disparities exist. Rural areas still struggle with access to neurology specialists and diagnostic tools. This has opened the door for tele-neurology platforms and home-based cognitive screening apps.

Insight: Reimbursement is no longer the barrier — care coordination and infrastructure are. Providers are racing to scale diagnostics faster than the patient base is growing.

 

Europe

Europe is gaining ground quickly, especially in countries with universal health coverage and centralized dementia strategies . The UK’s NHS , for instance, has rolled out memory clinics nationwide and recently added blood-based Alzheimer’s tests to pilot programs. Germany, Sweden, and the Netherlands have also prioritized early detection as a cost-containment strategy for long-term care.

The EU’s Joint Action on Dementia has created a cross-border framework for research, trial harmonization, and diagnostic access. As a result, more patients in mid-stage disease are getting biomarker-confirmed diagnoses — a huge shift from a decade ago when most cases went undetected.

However, Eastern Europe lags behind. Many countries still rely on symptomatic diagnosis without access to PET scans or advanced imaging, though investments in diagnostic capacity are picking up.

 

Asia Pacific

This is the fastest-growing region — and the one with the most urgent need. Japan , with its rapidly aging population, has made dementia a national health priority. It’s heavily funding neuroimaging , community-based memory screening , and preventive care programs .

 

China and India represent high-volume, under-penetrated markets. While access to PET and CSF testing is limited in rural areas, urban hospitals are rapidly expanding diagnostic infrastructure. Private hospital chains in India are offering cognitive check-up packages as part of annual health screenings — a sign that memory care is becoming more mainstream.

In South Korea , early-stage AI tools and mobile apps for cognitive health are seeing rapid uptake, especially among tech-savvy seniors.

That said, access isn’t uniform. In tier-2 and tier-3 cities, diagnosis is still rare, and stigma around cognitive decline remains high.

 

Latin America, Middle East & Africa (LAMEA)

This region remains underdiagnosed and underserved , but not static. Countries like Brazil and Mexico are piloting memory disorder screening programs at the primary care level, especially in urban health centers. These efforts are supported by NGOs and public health grants.

In the Middle East , countries like Saudi Arabia and the UAE are building specialized neurology units within flagship hospitals. Cognitive health is being woven into national aging strategies — a trend that may accelerate adoption of new diagnostic tools.

 

Africa , however, is still early in its memory care journey. The majority of patients remain undiagnosed, with memory loss often attributed to aging rather than clinical pathology. A few pilot programs using tablet-based screening tools and tele-neurology consults are emerging, especially in South Africa and Kenya.

 

Regional Snapshot Summary

Region	Market Outlook	Key Drivers
North America	High maturity	FDA-backed drug and diagnostic approvals, payer coverage, AI tools
Europe	Expanding access	Public health funding, memory clinic rollout, EU collaboration
Asia Pacific	Fastest growth	Aging population, private hospital investments, digital uptake
LAMEA	Early-stage	Public-private pilots, NGO initiatives, rising dementia burden

To be honest, access is the new frontier. You can’t treat what you can’t diagnose. That’s why diagnostics — especially low-cost, scalable tools — will define regional leadership in the next five years.

 

End-User Dynamics And Use Case

When it comes to memory disorders, the end users aren’t just clinicians — they’re entire ecosystems. From caregivers navigating daily routines to primary care physicians flagging early symptoms, the decision-making and adoption patterns vary widely across settings. Understanding how different stakeholders interact with diagnostic tools, therapeutics, and digital platforms is critical for market penetration.

Hospitals and Memory Clinics

This is where most formal diagnoses begin. Tertiary hospitals and neurology-specialized memory clinics are equipped with advanced imaging (like PET and MRI), access to CSF analysis, and trained staff to manage cognitive assessments. These settings are usually the first adopters of newly approved disease-modifying therapies , given the infrastructure required for infusion and close monitoring.

They also act as trial hubs. Many patients participating in clinical studies for Alzheimer’s or FTD drugs are recruited from these centers. As new plasma biomarkers gain approval, these clinics are expected to be the first to roll them into routine workups.

That said, capacity is stretched. Wait times for cognitive workups in top-tier hospitals often exceed six months in many countries.

 

Primary Care Providers (PCPs)

The front line of memory care. PCPs see patients long before formal cognitive issues emerge — during routine physicals or while managing comorbidities like hypertension or diabetes. With the rise of digital cognitive screening tools , many PCPs are starting to incorporate 5–10 minute tests into annual checkups, especially for older adults.

However, barriers remain. Most PCPs still lack the training and time to differentiate between normal aging and early cognitive decline. Tools that simplify triage and auto-generate referrals to neurology are gaining traction.

 

Long-Term Care and Assisted Living Facilities

These are key customers for remote monitoring platforms , medication adherence tools , and non-pharmacologic interventions . Cognitive decline in these settings is often moderate to severe, so the emphasis is on stabilization, behavioral management, and reducing caregiver burden.

Facilities are adopting tools like:

• Passive fall detectors

• Behavioral AI monitoring

• Virtual reality-based memory stimulation

• App-connected pill dispensers

Vendors who design for ease of use, not just accuracy , are winning here.

 

Home-Based Care and Caregiver Networks

An increasingly important segment. As aging in place becomes the preferred model, families are taking a more active role in managing early and mid-stage memory disorders. The demand for at-home diagnostics , mobile cognitive games , and telehealth support is climbing.

Digital health companies are targeting this segment with:

• Apps that track daily routines and cognitive changes

• Voice assistants that remind users to take meds or attend appointments

• Caregiver dashboards with remote patient updates

The emotional weight in this segment is high. Products that reduce anxiety for both patient and caregiver — without overcomplicating workflows — stand out.

 

Use Case Spotlight

A community hospital in Melbourne, Australia, piloted a memory health pathway starting at the primary care level. Using a digital cognitive screening tool embedded into the clinic’s EMR system, GPs began screening patients aged 60+ during routine appointments. Those flagged as high-risk were referred for blood-based biomarker testing and imaging.

In 9 months, early-stage Alzheimer’s diagnosis rates rose by 34%, and average time to diagnosis dropped from 14 months to 6 months. The hospital then layered in a remote care platform that supported medication reminders, symptom tracking, and caregiver check-ins.

Outcome? Better diagnosis, faster treatment starts, and a drop in emergency room visits linked to confusion or behavioral disturbances.

 

Key Takeaway

End-user needs vary wildly. A neurologist wants diagnostic precision. A caregiver wants simplicity. A long-term care nurse wants behavior management tools. The most successful solutions don’t pick one — they flex across these roles.

 

Recent Developments + Opportunities & Restraints

Over the past two years, the memory disorders landscape has shifted from cautious optimism to full-speed innovation. Regulatory wins, diagnostic breakthroughs, and novel treatment mechanisms have all played a role — but not without resistance from healthcare systems wrestling with cost, infrastructure gaps, and real-world feasibility.

Recent Developments (2023–2025)

• FDA Approval of Plasma-Based Alzheimer’s Diagnostic (2024) A groundbreaking blood test capable of detecting phosphorylated tau in plasma received FDA clearance for clinical use. This has triggered adoption pilots in both primary care and neurology clinics across North America and Europe.

• Eli Lilly’s Anti-Amyloid Drug Receives Conditional EMA Approval (2024) Eli Lilly’s biologic treatment for early Alzheimer’s was granted conditional marketing authorization in the EU — but with strong post-market data requirements due to safety concerns over ARIA events.

• Roche Partners with Cognito Therapeutics on Non-Invasive Neuromodulation (2025) In a bid to diversify beyond pharmacotherapy, Roche signed a multi-year partnership with Cognito to explore light and sound stimulation as a complementary therapy for mild cognitive impairment.

• Google Health Launches AI-Powered Cognitive Screening Tool (2023) Built into Android OS, this tool analyzes speech and typing patterns to detect subtle memory loss. It’s now used in over 50 senior care centers in pilot programs across Asia.

• CMS Expands Coverage for Alzheimer’s PET Imaging (2024) The U.S. Centers for Medicare & Medicaid Services updated its policy to include broader access to amyloid PET scans, provided results are linked to therapeutic decision-making.

 

Opportunities

• Mainstreaming of At-Home Cognitive Diagnostics With regulatory greenlights for blood-based biomarkers and FDA-recognized digital tools, there’s now a clear path to consumer-accessible memory screening. This shift could make early-stage intervention widely scalable — even outside of major hospital systems.

• Growing Demand in Emerging Economies Rapid aging in Asia and Latin America is driving demand for affordable, tech-enabled diagnostics. Cloud-based cognitive testing and mobile memory apps are gaining traction in these markets, where imaging infrastructure remains limited.

• Cross-Industry Integration Partnerships between pharma, AI firms, and digital health platforms are creating bundled solutions that span detection, treatment, and monitoring. This integration will likely shorten diagnosis timelines and boost adherence once treatment begins.

 

Restraints

• High Cost of Novel Therapies and Monitoring Disease-modifying biologics come with a steep price tag — often exceeding $25,000 per patient per year . Combined with PET scan monitoring and side effect management, the total cost of care is difficult to justify without long-term real-world outcomes.

• Specialist Bottlenecks and Diagnostic Gaps Despite digital advancements, most countries face a shortage of neurologists and geriatricians trained in cognitive disorders. Even with good tools, many patients go undiagnosed due to lack of access, awareness, or follow-up infrastructure.

Bottom line: The science is moving faster than the system. Until cost, access, and specialist capacity catch up, the market will keep running into practical limits — especially outside major urban centers.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 10.9 Billion
Revenue Forecast in 2030	USD 16.2 Billion
Overall Growth Rate	CAGR of 6.7% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Disorder Type, Diagnostic Method, Treatment Type, End User, Geography
By Disorder Type	Alzheimer’s, Mild Cognitive Impairment, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia
By Diagnostic Method	Neuroimaging, Biomarker Testing (CSF/Blood), Cognitive Assessment Tools, Genetic Testing
By Treatment Type	Cholinesterase Inhibitors, NMDA Antagonists, Disease-Modifying Therapies, Cognitive/Behavioral Interventions
By End User	Hospitals & Memory Clinics, Primary Care Providers, Long-Term Care Facilities, Home-Based Care
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, Japan, South Korea, India, Brazil, Australia
Market Drivers	- Growing aging population globally - Approval of disease-modifying therapies - Advances in AI-enabled cognitive diagnostics and plasma biomarkers
Customization Option	Available upon request